Skip to main content
. 2015 Jul 20;126(12):1415–1423. doi: 10.1182/blood-2015-03-635151

Figure 3.

Figure 3

Survival since the start of the protocol (D1 cladribine/Ara-C). (A) Overall survival. (B) Survival according to DAS10 evolution. Good responders (DAS decrease >4 points) appeared to have a better outcome than poor responders (DAS decrease ≤4 points) (P < .04).